to the brain and spinal cord. These approaches, to vary ing extents, offer the potential for the first time to not just compensate for nervous system injury after it has occurred, but to prevent or reduce ongoing cell loss.
The first step in generating a rational approach to dis ease therapy is to understand the basic biology of dis ease. In Parkinson's disease, dopamine depletion con tributes to symptomatology, and L-dopa replacement early in the disease is effective therapy. However, dopa mine replacement eventually fails, and some of the rea sons for this are described by the localization of the en zyme in the brain that converts L-dopa to dopamine, aromatic L-amino acid decarboxylase (AADC). Insuffi cient levels of AADC are present after nigrostriatal de nervation to produce adequate levels of dopamine (7) . An exciting alternative to the use of fetal tissue in animal models of Parkinson's disease is the delivery of therapeutic substances to the brain using gene therapy.
A convection-type infusion model for the delivery of in vivo gene therapy viral particles to the brain is discussed However, this approach has exhibited limited utility in the clinic. The efficacy of adrenal medullary autotrans plantation in primate models of Parkinson's disease may be enhanced by co-grafts with peripheral nerves (to en hance graft survival through growth factor release) plus INTRODUCTION dopamine replacement (6) . Whether this effect is suffi cient to justify another clinical trial with adrenal cografts remains to be determined.
Another human disease of the striatal system is Hun tington's disease, wherein amplified numbers of CAG repeats in the huntingtin gene ultimately result in striatal cell death. Treatment of striatal cultures with nerve growth factor actually decreases huntingtin gene expres sion, whereas treatment with fibroblast growth factor-2 increases huntingtin gene expression (5) . This finding highlights the fact that growth factor therapy can be a double-edged sword, and that careful preclinical studies in good animal models of human disease are a require ment for sensible clinical translation.
Alzheimer's disease has also been the subject of ex tensive preclinical research, including attempts to pre vent neuronal loss in animal models of this disease. Cholinergic neurons in the basal forebrain undergo pro found degeneration in Alzheimer's disease. Nerve growth factor can reverse atrophy of basal forebrain cholinergic neurons resulting from normal aging, and can prevent cholinergic neuronal loss after injury or ex citotoxic damage. However, the entry of NGF into the clinic has been limited by delivery problems. NGF must be administered intracerebrally due to its size and polar ity, but causes adverse effects if broadly distributed in the brain because of growth responses from nontargeted systems. It has been shown that intraparenchymal infu sions of NGF for a 2-week period can rescue injured cholinergic neurons without causing extensive parenchy mal damage (10) . This raises the possibility that intra parenchymal infusions might be a practical means of tar geting cholinergic neurons in the Alzheimer's brain with NGF, although longer term studies are needed.
Novel neural repair strategies are also gaining promi nence in nondegenerative disorders of the nervous sys tem. An intriguing means of addressing chronic neuro pathic pain with grafts of adrenal chromaffin cells is discussed (4) . A conditionally immortalized adrenal chromaffin-type cell line, when grafted into rats, will survive for extended time periods and exert antinocicep tive effects without evident adverse effects. This ap proach merits further exploration as a means of treating chronic pain, and indeed other investigators are conduct ing clinical trials of adrenal chromaffin cell grafts to the thecal space for chronic pain (2) .
This collection of articles is concluded by a review of a potential pitfall in the use of P-galactosidase histo chemistry as a marker of grafted cell survival. Many grafting studies utilizing genetically modified cells or stem cells incorporate the gene for E.coli P-galactosi dase as a marker of grafted cells. Sanchez-Ramos et al. (9) report potential pitfalls in the use of P-gal histochem istry as a marker of grafted cells, and provide solutions that should correct this problem. The report serves as a useful reminder that the tools and techniques of neurobi ology must be employed carefully and thoughtfully if we are to generate meaningful data that will reliably ex pand our knowledge of neurobiology, and move the field of neural repair forward from animal models into the clinic.
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